Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback